Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （股份代號：6821） 董事會會議日期 凱萊英醫藥集團（天津）股份有限公司（「本公司」）董事會（「董事會」）謹此公佈， 董事會會議將於2026年3月30日（星期一）舉行，藉以（其中包括）考慮及批准本公 司及其附屬公司截至2025年12月31日止年度業績及其發佈，並考慮建議派發末期 股息（如有）。 承董事會命 凱萊英醫藥集團（天津）股份有限公司 Hao Hong博士 於本公告日期，本公司董事會由董事長兼執行董事Hao Hong博士，執行董事楊蕊 女士、張達先生及洪亮先生，非執行董事Ye Song博士及張婷女士，以及獨立非 執行董事孫雪嬌博士、侯欣一博士及謝維愷先生組成。 董事長、執行董事兼首席執行官 中國天津，2026年3月16日 ...

格隆汇3月16日丨凯莱英(06821.HK)公布，董事会会议将于2026年3月30日（星期一）举行，藉以（其中 包括）考虑及批准公司及其附属公司截至2025年12月31日止年度业绩及其发布，并考虑建议派发末期股 息（如有）。 ...

格隆汇3月16日丨凯莱英(06821.HK)公布，董事会会议将于2026年3月30日（星期一）举行，藉以（其中 包括）考虑及批准公司及其附属公司截至2025年12月31日止年度业绩及其发布，并考虑建议派发末期股 息（如有）。 ...

凱萊英醫藥集團（天津）股份有限公司（「本公司」）董事會（「董事會」）謹此公佈， 董事會會議將於2026年3月30日（星期一）舉行，藉以（其中包括）考慮及批准本公 司及其附屬公司截至2025年12月31日止年度業績及其發佈，並考慮建議派發末期 股息（如有）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 董事會會議日期 承董事會命 凱萊英醫藥集團（天津）股份有限公司 Hao Hong博士 董事長、執行董事兼首席執行官 中國天津，2026年3月16日 於本公告日期，本公司董事會由董事長兼執行董事Hao Hong博士，執行董事楊蕊 女士、張達先生及洪亮先生，非執行董事Ye Song博士及張婷女士，以及獨立非 執行董事孫雪嬌博士、侯欣一博士及謝維愷先生組成。 ...

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry as of March 16, 2026 [1] Core Insights - The report emphasizes the importance of products with price leadership amid rising costs in the supply chain due to geopolitical tensions and policy changes affecting raw material prices [2] - The report highlights the significant price increases in pharmaceutical raw materials, particularly vitamins and amino acids, which have seen price increases of 40.54% and 84.66% respectively since the beginning of the year [2] - The report notes the approval of China's first invasive brain-machine interface, marking a significant milestone in the medical device sector [5] - The report indicates a strong trend in China's innovative pharmaceuticals going global, with a notable increase in licensing-out transactions [6] Summary by Sections 1. Supply Chain Dynamics - The report discusses the impact of rising prices in upstream chemical products on pharmaceutical raw materials, stressing that the ability to pass on these costs is crucial for maintaining profitability [2] - It mentions that 90% of monitored products have seen price increases, with the chemical product price index rising by 28.52% since the beginning of the year [2] 2. Market Trends in Disposable Gloves - The report details the price increases in disposable nitrile gloves and PVC gloves due to rising costs of raw materials like butadiene and acrylonitrile, which have increased by 84.43% and 47.30% respectively [3] - It notes that the domestic utilization rate for nitrile gloves has improved, and export prices have been rising since late 2025 [3] 3. Regulatory Environment - The report highlights the impact of dual-use item management on the pricing of key materials, creating significant price disparities between domestic and international markets [4] - It suggests that stricter controls on resources like rare earths could enhance the competitive advantage of domestic medical products [4] 4. Innovations in Medical Devices - The report discusses the approval of the brain-machine interface by the National Medical Products Administration, which is expected to open new market opportunities [5] - It outlines the potential for significant market growth in this area, given the high number of spinal cord injury patients in China [5] 5. International Expansion of Chinese Pharmaceuticals - The report notes that there have been 39 licensing-out transactions in the innovative drug sector, with upfront payments totaling approximately $2.953 billion [6] - It emphasizes that the trend of Chinese pharmaceuticals going global continues to strengthen, with a focus on small nucleic acid drugs and dual antibodies [7] 6. Stock Recommendations - The report recommends focusing on raw material suppliers with price leadership, such as Zhejiang Medicine and Chuan Ning Biological, and highlights companies like Inco Medical and Blue Sail Medical in the disposable glove sector [8] - It also suggests monitoring companies involved in the invasive brain-machine interface and small nucleic acid drugs, indicating potential for growth in these areas [8]

Group 1 - The company held its fifth board meeting on March 13, 2026, where all 9 attending directors approved several resolutions [2][4] - The board approved the repurchase and cancellation of 61,000 A-share restricted stocks from 5 departing incentive recipients as per the 2025 A-share restricted stock incentive plan [2][21] - The company plans to amend its articles of association to reflect changes in registered capital from 360,593,720 yuan to 360,780,970 yuan due to stock repurchase [6][7] Group 2 - The board approved the revision of the company's ESG management policy for suppliers to enhance sustainable development practices [9][10] - The company will use up to 450 million yuan of idle funds to purchase low-risk financial products to improve fund utilization efficiency [11][28] - The board authorized the management to make investment decisions within the approved limits for the financial products [31][32] Group 3 - The repurchase price for the restricted stocks is set at 36.42 yuan per share for the initial grant and 53.24 yuan per share for the reserved grant [21] - The total amount for the stock repurchase is 2,305,720 yuan, sourced from the company's own funds [22] - The repurchase will not materially affect the company's financial status or operational results, nor will it impact the ongoing stock incentive plan [23][24]

Core Viewpoint - The company Kailaiying (06821) has announced a plan to utilize idle self-owned funds for purchasing financial products, indicating a strategic move to optimize asset management and enhance returns [1] Group 1: Company Announcement - The company will hold its fifth board meeting on March 13, 2026, to review and approve the proposal regarding the use of idle self-owned funds [1] - The approved amount for purchasing short-term financial institution products is not to exceed 4.5 billion RMB (or equivalent foreign currency) [1] - The usage period for these funds is set to be within 12 months from the date of the board's approval, allowing for the funds to be recycled within the specified limit and timeframe [1]

Core Viewpoint - The company Kailaiying (002821) has announced a plan to utilize idle self-owned funds for purchasing financial products, indicating a strategic move to optimize asset management and enhance returns [1] Group 1: Financial Strategy - The company will hold its fifth board meeting on March 13, 2026, to review and approve the proposal regarding the use of idle self-owned funds [1] - The approved amount for purchasing short-term financial institution products is up to 4.5 billion RMB (or equivalent foreign currency), which reflects a significant allocation of resources [1] - The usage period for these funds is set for 12 months from the date of board approval, allowing for flexibility in fund management as the funds can be recycled within this timeframe [1]

Core Viewpoint - Kailaiying Pharmaceutical Group (Tianjin) Co., Ltd. has approved the use of idle self-owned funds to purchase financial products, indicating a strategic move to optimize asset management and enhance returns on available capital [1] Group 1 - The company will utilize an amount not exceeding 4.5 billion RMB (or equivalent foreign currency) for the purchase of short-term financial institution products [1] - The approval was made during the seventh meeting of the fifth board of directors held on March 13, 2026 [1] - The usage period for these funds is set within 12 months from the date of the board's approval, allowing for the funds to be recycled within the specified limit and timeframe [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 茲載列本公司在深圳證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 凱萊英醫藥集團（天津）股份有限公司 Hao Hong博士 董事長、執行董事兼首席執行官 中國天津，二零二六年三月十三日 於本公告日期，本公司董事會由董事長兼執行董事 Hao Hong 博士，執行董事楊蕊女士 、張達先生及洪亮先生，非執行董事 Ye Song 博士及張婷女士，以及獨立非執行董事孫 雪嬌博士、侯欣一博士及謝維愷先生組成。 凯莱英医药集团（天津）股份有限公司 供应商ESG管理政策 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第13.10B條作出。 （2026年3月修订） 凯莱英医药集团（天津）股份有 ...